|
1 Cardiac Anatomy and Pathophysiology of Coronary Circulation as a Basis for Imaging |
|
|
1 | (14) |
|
|
|
|
|
|
|
|
|
1 | (1) |
|
|
|
2 | (1) |
|
|
|
3 | (2) |
|
|
|
3 | (1) |
|
1.3.2 Mechanical Activity of the Heart |
|
|
3 | (1) |
|
1.3.3 Electrical Activity of the Heart |
|
|
4 | (1) |
|
|
|
5 | (1) |
|
1.5 Myocardial Perfusion Imaging |
|
|
5 | (6) |
|
1.5.1 Single-Photon Agents Used for Perfusion Imaging |
|
|
6 | (2) |
|
1.5.2 Single-Photon Data Acquisition |
|
|
8 | (2) |
|
1.5.3 PET and Myocardial Perfusion |
|
|
10 | (1) |
|
1.6 Radionuclide Evaluation of Ventricular Function |
|
|
11 | (2) |
|
|
|
11 | (1) |
|
|
|
12 | (1) |
|
1.7 Imaging Cardiac Neurotransmission |
|
|
13 | (2) |
|
|
|
14 | (1) |
|
2 How Should We Stress the Human Heart? |
|
|
15 | (14) |
|
|
|
|
|
15 | (1) |
|
|
|
15 | (2) |
|
|
|
16 | (1) |
|
|
|
16 | (1) |
|
|
|
16 | (1) |
|
2.2.4 Diagnostic Performance and Accuracy |
|
|
17 | (1) |
|
|
|
17 | (1) |
|
2.3 Pharmacological Agents |
|
|
17 | (7) |
|
|
|
17 | (3) |
|
|
|
20 | (1) |
|
|
|
20 | (1) |
|
|
|
21 | (2) |
|
2.3.5 Diagnostic Performance and Accuracy |
|
|
23 | (1) |
|
|
|
23 | (1) |
|
|
|
24 | (1) |
|
|
|
24 | (1) |
|
|
|
24 | (1) |
|
|
|
24 | (1) |
|
|
|
24 | (1) |
|
2.4.5 Diagnostic Performance and Accuracy |
|
|
25 | (1) |
|
|
|
25 | (1) |
|
|
|
25 | (4) |
|
|
|
26 | (3) |
|
3 Myocardial Perfusion Imaging: The Role of SPECT, PET and CMR |
|
|
29 | (22) |
|
|
|
Berlinda J. de Wit-van der Veen |
|
|
|
|
|
|
|
|
|
|
29 | (1) |
|
3.2 Single Photon Emission Computed Tomography |
|
|
29 | (8) |
|
3.2.1 Principles of Myocardial Perfusion Imaging |
|
|
30 | (2) |
|
3.2.2 Identifying CAD Using SPECT |
|
|
32 | (2) |
|
3.2.3 Quantifying Relative Perfusion and Function |
|
|
34 | (2) |
|
3.2.4 Clinical Value of Gated MPS |
|
|
36 | (1) |
|
3.3 Positron Emission Tomography |
|
|
37 | (5) |
|
3.3.1 Principles of Perfusion PET |
|
|
37 | (2) |
|
3.3.2 CAD Identification Using PET |
|
|
39 | (2) |
|
3.3.3 Myocardial Viability Imaging |
|
|
41 | (1) |
|
3.3.4 Clinical Utility of Perfusion PET in Assessing CAD |
|
|
41 | (1) |
|
3.4 Perfusion Cardiovascular Magnetic Resonance |
|
|
42 | (2) |
|
3.4.1 Basic Principles of CMR Perfusion |
|
|
42 | (1) |
|
3.4.2 Image Interpretation |
|
|
42 | (1) |
|
3.4.3 Additional Imaging Protocols in Cardiovascular Magnetic Resonance Imaging |
|
|
43 | (1) |
|
3.4.4 Diagnostic Value and Clinical Advantages of CMR Perfusion Imaging |
|
|
44 | (1) |
|
|
|
44 | (2) |
|
3.5.1 Cardiac Hybrid Imaging |
|
|
45 | (1) |
|
3.5.2 Myocardial Computed Tomography Perfusion |
|
|
45 | (1) |
|
|
|
46 | (5) |
|
|
|
48 | (3) |
|
4 Innervation of the Heart: Imaging Findings Using [ 123I]-MIBG Scintigraphy in Different Pathologies |
|
|
51 | (20) |
|
|
|
|
|
|
|
|
|
51 | (14) |
|
4.1.1 Sympathetic Innervation |
|
|
51 | (2) |
|
4.1.2 From Guanethidine to Meta-Iodobenzylguanidine |
|
|
53 | (2) |
|
4.1.3 [ 123I]-MIBG Myocardial Scintigraphy |
|
|
55 | (1) |
|
4.1.4 Normal Databases of Cardiac MIBG |
|
|
56 | (3) |
|
4.1.5 [ 123I]-MIBG Imaging in Cardiac Pathologies |
|
|
59 | (6) |
|
4.2 Cardiac Neurotransmission Imaging Using [ 123I]-MIBG Scintigraphy in Brain Disease |
|
|
65 | (3) |
|
4.2.1 Pathological Backgrounds |
|
|
65 | (1) |
|
4.2.2 [ 123I]-MIBG Findings in Parkinson's Disease |
|
|
66 | (1) |
|
4.2.3 [ 123I]-MIBG Findings in Dementia with Lewy Bodies |
|
|
67 | (1) |
|
4.2.4 Other Neurological Diseases |
|
|
68 | (1) |
|
|
|
68 | (3) |
|
|
|
69 | (2) |
|
5 How to Reduce the Radiation Burden in Cardiac CT |
|
|
71 | (20) |
|
|
|
|
|
71 | (2) |
|
5.2 How is Radiation Dose Estimated in MDCT Coronary Angiography |
|
|
73 | (1) |
|
5.3 A Brief History of MDCT Coronary Angiography |
|
|
74 | (1) |
|
5.4 Strategies to Minimize Radiation Dose from Cardiac MDCT |
|
|
74 | (8) |
|
5.4.1 Scan Length Optimization |
|
|
75 | (1) |
|
5.4.2 Tube Voltage and Tube Current Setup |
|
|
75 | (1) |
|
5.4.3 ECG-Triggered Tube-Current Modulation |
|
|
76 | (1) |
|
5.4.4 Dual-Source Computed Tomography |
|
|
77 | (1) |
|
5.4.5 Prospective ECG Triggering |
|
|
78 | (1) |
|
5.4.6 Increase in Number of Slices |
|
|
79 | (1) |
|
5.4.7 Adaptive Iterative Reconstruction Algorithm |
|
|
80 | (1) |
|
5.4.8 High-Pitch Computed Tomography Coronary Angiography |
|
|
81 | (1) |
|
5.5 Radiation Dose Associated with Different Generations of MDCT |
|
|
82 | (4) |
|
5.5.1 Low Generation Scanner Up to 64-MDCT |
|
|
82 | (1) |
|
|
|
83 | (1) |
|
5.5.3 Prospective ECG-Triggering |
|
|
83 | (1) |
|
5.5.4 Dual Source Computed Tomography |
|
|
84 | (1) |
|
5.5.5 256- and 320-MDCT Scanner |
|
|
85 | (1) |
|
5.5.6 Adaptive Statistical Iterative Reconstruction Algorithm (ASIR) |
|
|
85 | (1) |
|
|
|
86 | (1) |
|
5.6 Patient Preparation and Contrast Agent Protocol |
|
|
86 | (2) |
|
|
|
88 | (3) |
|
|
|
88 | (3) |
|
6 How to Reduce the Radiation Burden in Cardiac SPECT |
|
|
91 | (12) |
|
|
|
|
|
6.1 Introduction: Living at the Time of "The Radiation Issue" |
|
|
91 | (1) |
|
6.2 Advances in Single-Photon-Emission Computed Tomography Cameras |
|
|
92 | (3) |
|
6.2.1 Cadmium-Zinc-Telluride Technology |
|
|
92 | (1) |
|
6.2.2 Other SPECT Cameras |
|
|
93 | (2) |
|
6.3 Advances in Reconstruction Software |
|
|
95 | (1) |
|
6.4 One Face of the Coin: Reducing Imaging Time and Saving Money |
|
|
95 | (2) |
|
6.5 The Other Face of the Coin: Reducing Dose and Radiation Burden to the Patient |
|
|
97 | (2) |
|
6.6 Conclusion: Nuclear Cardiology at the Time of the "Ulysses Syndrome" |
|
|
99 | (4) |
|
|
|
100 | (3) |
|
7 Will 3D Imaging of the Heart Replace Pathology? |
|
|
103 | (12) |
|
|
|
|
|
|
|
103 | (1) |
|
7.1.1 Limitations of 2D Imaging |
|
|
103 | (1) |
|
7.1.2 Possibilities Using 3D Imaging |
|
|
103 | (1) |
|
7.2 Anatomical Measurements |
|
|
104 | (2) |
|
7.2.1 Left Ventricular Morphology |
|
|
104 | (1) |
|
7.2.2 Right Ventricular Function |
|
|
104 | (1) |
|
7.2.3 Myocardial Performance |
|
|
105 | (1) |
|
7.3 Functional Evaluation |
|
|
106 | (2) |
|
7.3.1 Functional Risk Assessment Versus Noninvasive Coronary Angiography |
|
|
107 | (1) |
|
7.4 Myocardial Fibrosis: 3D Evaluation of Interstitium |
|
|
108 | (2) |
|
7.4.1 Cardiac Magnetic Resonance Methods |
|
|
108 | (1) |
|
7.4.2 Nuclear Cardiology Techniques |
|
|
109 | (1) |
|
7.4.3 Contractile Reserve |
|
|
109 | (1) |
|
7.4.4 Cardiac Innervation |
|
|
109 | (1) |
|
7.5 Myocardial Perfusion Imaging and Revascularization |
|
|
110 | (1) |
|
7.6 Proper Diagnostic Workup |
|
|
111 | (1) |
|
|
|
111 | (4) |
|
|
|
111 | (4) |
|
8 Image Fusion and Coregistration: State of the (He)art |
|
|
115 | (10) |
|
|
|
|
|
|
|
|
|
115 | (1) |
|
8.2 Regulatory Issues and Software Development |
|
|
115 | (1) |
|
8.3 Combining Functional and Morphology Data: Individualized Analysis |
|
|
116 | (1) |
|
8.4 Necessary Prerequisite: Coregistration |
|
|
116 | (1) |
|
8.5 Tools for Hybrid Cardiac Imaging |
|
|
117 | (2) |
|
8.5.1 Extensions to CTA Visualization Tools |
|
|
117 | (1) |
|
8.5.2 Integration of the Coronary Tree into Tools for Nuclear Cardiology |
|
|
118 | (1) |
|
8.6 Going Beyond Perfusion SPECT/PET/CTA |
|
|
119 | (2) |
|
|
|
121 | (1) |
|
|
|
122 | (3) |
|
|
|
122 | (3) |
|
9 Diagnostic Algorithms in Patients with Suspected Coronary Artery Disease: Guidelines and Evidence-Based Behaviors |
|
|
125 | |
|
|
|
|
|
|
|
125 | (1) |
|
9.2 Epidemiology and Clinical Presentation of Coronary Artery Disease |
|
|
125 | (1) |
|
|
|
125 | (1) |
|
9.2.2 Unstable Angina and Non-ST-Elevated Myocardial Infarction |
|
|
126 | (1) |
|
9.2.3 ST-Elevated Myocardial Infarction |
|
|
126 | (1) |
|
9.2.4 Heart Failure and Sudden Cardiac Death |
|
|
126 | (1) |
|
9.3 Diagnosis of Coronary Artery Disease |
|
|
126 | (4) |
|
9.3.1 Assessment of Pretest Probability |
|
|
126 | (2) |
|
9.3.2 Cardiac Radionuclide Imaging |
|
|
128 | (1) |
|
9.3.3 Stress Echocardiography |
|
|
129 | (1) |
|
9.3.4 Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging |
|
|
130 | (1) |
|
9.4 Diagnostic Strategies in Asymptomatic Patients |
|
|
130 | (1) |
|
9.5 Diagnostic Strategies in Patients with Suspected ACS |
|
|
131 | (1) |
|
|
|
132 | |
|
|
|
132 | |